Tc-99m-MIBI scintigraphy in untreated stage III multiple myeloma: Comparison with X-ray skeletal survey and bone scintigraphy

dc.contributor.buuauthorAlper, Eray
dc.contributor.buuauthorGürel, M.
dc.contributor.buuauthorEvrensel, Türkkan
dc.contributor.buuauthorÖzkocaman, Vildan
dc.contributor.buuauthorAkbunar, T.
dc.contributor.buuauthorDemiray, Mutlu
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Nükleer Tıp Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-9732-5340tr_TR
dc.contributor.researcheridAAJ-1027-2021tr_TR
dc.contributor.researcheridAAH-1854-2021tr_TR
dc.contributor.scopusid7006827670tr_TR
dc.contributor.scopusid7004283569tr_TR
dc.contributor.scopusid6603942124tr_TR
dc.contributor.scopusid6603145040tr_TR
dc.contributor.scopusid6506964123tr_TR
dc.contributor.scopusid6603631569tr_TR
dc.date.accessioned2022-03-16T07:29:55Z
dc.date.available2022-03-16T07:29:55Z
dc.date.issued2003-05
dc.description.abstractTechnetium-99m 2-methoxyisobutylisonitrile (99mTc-MIBI) is a lipophilic agent that has been proposed as a useful tracer for the detection of disease sites in patients with multiple myeloma (MM). We performed a prospective study to determine the potential of 99mTc-MIBI imaging for the evaluation of the extent of primary disease in patients with advanced stage MM, compared with skeletal survey and bone scintigraphy. Twenty patients with advanced stage MM at initial diagnosis underwent whole-body 99mTc-MIBI imaging, together with contemporaneous skeletal survey and bone scintigraphy. The findings of 99mTc-MIBI imaging were correlated with the results of skeletal survey and bone scan. All 99mTc-MIBI scans were positive for the presence of active MM, whereas skeletal surveys were positive in 18 patients (90%) with osteolytic lesions. Bone scintigraphy demonstrated MM in only 15 patients (75%). In two patients with no detectable lesions on skeletal survey, 99mTc-MIBI imaging revealed uptake in the spine, corresponding to the abnormalities seen on magnetic resonance imaging (MRI). With respect to the localization of bone lesions, 99mTc-MIBI imaging was superior to bone scintigraphy in 15 patients (75%) and had concordant results with bone scintigraphy in four (20%). 99mTc-MIBI imaging is a very sensitive imaging modality for the identification of the extent of disease in patients with advanced MM. It is clearly superior to bone scintigraphy and complements the results of skeletal survey by finding additional disease sites. Hence, in active MM patients, 99mTc-MIBI imaging has the potential to detect bone marrow disease that cannot be detected by skeletal survey and bone scintigraphy.en_US
dc.identifier.citationAlper, E. vd. (2003). “Tc-99m-MIBI scintigraphy in untreated stage III multiple myeloma: Comparison with X-ray skeletal survey and bone scintigraphy”. Nuclear Medicine Communications, 24(5), 537-542.en_US
dc.identifier.endpage542tr_TR
dc.identifier.issn0143-3636
dc.identifier.issue5tr_TR
dc.identifier.pubmed12717071tr_TR
dc.identifier.scopus2-s2.0-0346225572tr_TR
dc.identifier.startpage537tr_TR
dc.identifier.urihttps://doi.org/10.1097/00006231-200305000-00009
dc.identifier.urihttp://hdl.handle.net/11452/25065
dc.identifier.volume24tr_TR
dc.identifier.wos000183007800009tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherLippincott Williams and Wilkinsen_US
dc.relation.journalNuclear Medicine Communicationsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRadiology, nuclear medicine and medical imagingen_US
dc.subject99mTc-MIBIen_US
dc.subjectBone scintigraphyen_US
dc.subjectMultiple myelomaen_US
dc.subjectRadiographyen_US
dc.subjectLesionsen_US
dc.subjectMarrowen_US
dc.subjectScanen_US
dc.subject.emtreeDiagnostic agenten_US
dc.subject.emtreeMedronate technetium Tc 99men_US
dc.subject.emtreeMethoxy isobutyl isonitrile technetium Tc 99men_US
dc.subject.emtreeRadiopharmaceutical agenten_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBone marrow canceren_US
dc.subject.emtreeBone tumoren_US
dc.subject.emtreeCancer stagingen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeComparative studyen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMethodologyen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreeMultiple myelomaen_US
dc.subject.emtreePathologyen_US
dc.subject.emtreeRadiographyen_US
dc.subject.emtreeReproducibilityen_US
dc.subject.emtreeScintiscanningen_US
dc.subject.emtreeSensitivity and specificityen_US
dc.subject.emtreeValidation studyen_US
dc.subject.emtreeWhole body countingen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 and overen_US
dc.subject.meshBone marrow neoplasmsen_US
dc.subject.meshBone neoplasmsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshMultiple myelomaen_US
dc.subject.meshNeoplasm stagingen_US
dc.subject.meshRadiopharmaceuticalsen_US
dc.subject.meshReproducibility of resultsen_US
dc.subject.meshSensitivity and specificityen_US
dc.subject.meshTechnetium Tc 99m medronateen_US
dc.subject.meshTechnetium Tc 99m sestamibien_US
dc.subject.meshWhole-body countingen_US
dc.subject.scopusMultiple Myeloma; Magnetic Resonance Imaging; Monoclonal Immunoglobulinemiaen_US
dc.subject.wosRadiology, nuclear medicine and medical imagingen_US
dc.titleTc-99m-MIBI scintigraphy in untreated stage III multiple myeloma: Comparison with X-ray skeletal survey and bone scintigraphyen_US
dc.typeArticle
dc.wos.quartileQ3en_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: